Health


Recent Health Stories

A new stem cell study reveals how APOL1 kidney risk variants quietly drain energy from podocytes, leaving them vulnerable when inflammation strikes. By growing patient-derived mini kidneys in the lab, researchers traced chronic kidney damage back to failing mitochondria, opening the door to more precise treatments for APOL1-mediated disease.
Study shows APOL1 kidney risk variants cripple podocyte mitochondria under inflammation, pointing to new targeted CKD therapies.
Rebecca Shavitupda